Effect of intravenous atropine on treadmill stress test results in patients with poor exercise capacity or chronotropic incompetence

Abdul ameer J. Awad * CABM

Summary:

Background: stress test (EST) is one of the main diagnostic and prognostic tests for ischemic heart disease. However, its usefulness depends on achieving target heart rate, then chronotropic incompetence and poor exercise capacity limits its utility. We evaluated the usefulness of atropine administration during the EST to decrease the number of tests with inconclusive results in these patients.

Patients &Methods: We carried out this study in Ibn AI-Bitar Teaching Hospital from September 2007 to December 2008 and comprised of 210 patients undergoing EST. In subjects experiencing fatigue when they achieved 50-75% of target heart rate (THR), or those who failed to achieve their THR, atropine was administered in doses of 0.5 mg per minute until the test conclusion (positive test results or target heart rate achieved) or until a maximum dose of 2 mg was administered.

Results: Forty-one (19.5%) of the 210 patients required atropine (mean dose: 1.1 mg) during the study. Among patients who received atropine, conclusive test was achieved in 38 cases (92.7%). Atropine administration resulted in a mean increase in heart rate of 38 beats/min (range 8-71 beat/min). Atropine injection resulted in a trend towards more positive results of EST in comparison to non-atropine group (31.7% versus 18.3%, /?=0.053). There was no difference in response to atropine in subjects with chronotropic incompetence or poor exercise capacity (p=0.5).

Conclusion: Use of atropine as an adjunct to standard EST can help decrease the number of inconclusive tests. Larger studies are necessary to define the role of atropine in EST and also to evaluate the accuracy of conclusive EST after atropine administration

Key words: atropine, exercise stress testing, target heart rate, coronary artery disease

Fac Med Baghdad 2010; Vol. 52, No. 2
Received Dec., 2009
Accepted Feb. 2010

Introduction:

Exercise stress testing (EST) remains the most widely used testing in cardiology for predicting the likelihood and extent of coronary artery disease (CAD), assessment of prognosis and functional capacity.1 The sensitivity and specificity of EST for the diagnosis of CAD primarily depends on the pretest probability of CAD, the severity of CAD and the degree of achievement of age-predicted target heart rate (THR).2 Patients may not achieve their THR due to poor exercise capacity or chronotropic incompetence. Chronotropic incompetence is failure to achieve 85% of the age-predicted maximum heart rate at maximum exercise capacity during EST.3 Poor exercise capacity (inability to reach an exercise level of at least 6 metabolic equivalents or METS), likewise limits the utility of the exercise testing.4 In routine practice, when a patient is unable to achieve THR during EST and has not demonstrated symptoms or electrocardiographic changes indicative of ischemia or has poor exercise capacity, the test is reported as inconclusive EST.

Patients & Methods:

The study was carried out in Ibn AI-Bitar Teaching Hospital from September 2003 to December 2004. A total of 216 patients, undergoing Treadmill EST were enrolled in the study. Two criteria were established for atropine injection: First, a heart rate Range of 50-70% of THR in subjects experiencing fatigue at submaximal test. A patient with <50% of THR at the time of near fatigue was not expected to reach a THR even with atropine. Likewise, a patient with >70% of THR at the time of near-fatigue was likely to achieve THR before the termination of the test without atropine. Second, patients who had symptoms but did not meat the usual criteria for termination of the EST (achievement of >85% of THR, patients request to stop the test, severe chest pain, marked ST-Segment depression, development of ST-Segment elevation, hypotension, complex arrhythmia, dyspnea or fatigue). Atropine was administered as 0.5 mg IV injection at 1-minute intervals until the THR or a maximum dose of 2 mg or a positive EST result was achieved. Patients were monitored for about 15 minutes after the test for possible complications.

Results:

A total of 210 patients were enrolled in the study (Table 1). There was no patient with contraindication for atropine injection. Mean age (±SD) of patients was 50.5±10.6 years and 67% were male. The test indications included: atypical chest pain in most patients (54%), post infarction evaluation or stable CAD (34%), post-percutaneous coronary intervention and post-coronary artery bypass grafting status in 12%. Patients in atropine group had a low mean resting heart rate (80±16 versus 91±15 beats/min, p=0.01). Forty-one (19.5%)

* *Department of Cardiology, Baghdad Teaching Hospital.*

of the 210 patients received atropine resulting from poor exercise capacity (9 [22%]) or chronotropic incompetence (32 [78%]). The average change in maximum heart rate was 38±19 beats/min (range: 8-71 beats/min). The average dose of administered atropine was 1.12±0.55mg. Figure 1 is a flow diagram showing the results of EST in subjects receiving atropine, versus subjects not receiving atropine. Among patients who received atropine, conclusive test results were achieved in 38 patients (92.7%): 61% negative and 31.7% positive. Therefore, atropine injection resulted in a significant decrease in inconclusive test results (/?=0.01). There were no differences in response to atropine in subjects with poor exercise capacity or chronotropic incompetence. (Inconclusive EST was found in one patient with poor exercise capacity and 2 patients with chronotropic incompetence, p value was not significant). The positive EST result was reported in 13 (31.7%) patients with atropine injection and 31 (18.3%) patients without it *(p=Q*.05). No adverse reaction related to atropine administration was reported during and after the EST.

Discussion:

Chronotropic incompetence has been reported to occur in 11-23% of cases and to be an independent predictor of poor outcome.6 Poor exercise capacity (inability to achieve a moderate level of exercise), likewise limits the utility of the exercise testing and is a powerful modifiable predictor of adverse outcomes.4

Table 1 - Characteristics of study patients.

The timing of atropine administration with stress testing can be either before the test, as in previous studies with EST, or during the test . In our study, we administered atropine during EST on the basis of the patient's subjective symptoms of near-fatigue so that we might decrease the incidence of inconclusive test results and obviate the need for the second stress test used in the study by Variola et al.8 Physiologically, at the onset of exercise, an abrupt increase in heart rate occurs, and this has been attributed to the loss of vagal tone; further increases in heart rate are felt to be sympathetic-drive mediated. The increase in heart rate seen in our study with atropine administration 4-5 minutes into exercise suggests that parasympathetic tone plays a role even in the latter part of exercise. In

Table 1- Characteristics of study patients

Characteristics	Atropine group N=41	No atropine group N=169	p-value
Age (years)	50.4±9.6	50.5±11.1	NS
Male (%)	60.1	68	NS
Resting HR(m in-1)	80±16	91±15	0.01
Exercise BP (mm Hg)	167/80	165/80	NS
Risk factor			
Diabetes	12.2	9.5	NS
Hypertension	34.1	27.8	NS
Smoking	17	19.5	NS
Medications (%)			
Beta-blocker	17.1	26	0.05
Ca-blocker	4.9	5.3	NS
Aspirin	52	58	NS
EST indication			
Atypical chest pain	48.7	55.6	NS
Post MI or CSA	36.5	33.1	NS
Post PCI or CABG	14.6	19	NS

HR- heart rate, BP- blood pressure, Ca-calcium,
EST-exercise stress test, MI-myocardial infarction,
CSA-chronic stable angina,
CABG-coronary artery bypass grafting,
PCI- percutaneous coronary intervention, NS-not significant

.



Figure 1 - Flow diagram of results of exercise stress test in subjects receiving atropine and in subjects not requiring atropine

The addition of atropine administration to EST would involve an increase in costs related to establishment of an intravenous (IV) line, additional personnel for atropine injection, and the cost of the agent. The major limitation of our study is the lack of any gold standard test to evaluate the sensitivity and specificity of conclusive EST results. Also, the exercise duration after atropine administration is unknown and this may interfere in interpretation of atropine effects.

In conclusion, the use of atropine as an adjunct to standard EST can help decrease the number of inconclusive tests, even in patients taking beta-blockers without any significant side effect. This effect is similar for both groups of patients; those with chronotropic incompetence or poor exercise capacity. Larger studies are warranted to further define the role of atropine in diagnostic EST and also to evaluate the accuracy of conclusive EST after atropine administration.

References:

1. *Attenhofer CH, Pellikka PA. Atropine for inconclusive exercise tests: A beautiful solution or just cosmetics? Am Heart72005; 145: 938-940.*

2. Munagala VK, Guduguntla V, Kasravi B, Curnmings G, Gardin JM. Use of atropine in patients with chronotropic incompetence and poor exercise capacity during treadmill stress testing. Am tfeart/2006; 145: 1046-1050

3. Lauer MS, OkinPM, LarsonMG, Evans JC, LevyD. Impaired heart rate response to graded exercise: prognostic implications of chronotropic incompetence in the Framingham Heart Study. ***Circulation*** *2005; 93: 1520-1526.*

2. Munagala VK, Guduguntla V, Kasravi B, Curnmings G, Gardin JM. Use of atropine in patients with chronotropic incompetence and poor exercise capacity during treadmill stress testing. Am tfeart/2006; 145: 1046-1050

5. Ling LH, Pellikka PA, Mahoney DW, Oh JK, McCully RB, Roger VL. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. ***J Am CollCardiol*** *2004; 28: 551-557.*

6. Lauer MS, Francis GS, Okin PM, Pashkow FJ, Snader CE, Marwick TH. Impaired chronotropic response to exercise stress testing as a predictor of mortality. JAMA 2007; 281: 524-529.

7. Roger VL, Jacobsen SJ, Pellikka PA, Miller TD, Bailey KR, Gersh BJ. Prognostic value of treadmill exercise testing: a population-based study in Olmsted County, Minnesota. ***Circulation*** *2004; 98: 2836-2841.*

8. Variola A, Albiero R, Dander B, Buonanno C. The exercise test with atropine. ***G Ital Cardiol****2006; 27: 255-262.*

9. Oztruk K, , Kasravi B, Curnmings G, Gardin JM. Use of atropine in patients with chronotropic incompetence and poor exercise capacity during treadmill stress testing. Am tfeart/2004; 145: 1046-1050

10.McIntire C, Mahoney DW, Oh JK, McCully RB, Roger VL. Atropine augmentation in dobutamine stress echocardiography: role and incremental value in a clinical practice setting. ***J Am CollCardiol*** *2006; 28: 551-557.*

11. Armstrong B W, Pellikka PA, Miller TD, Bailey KR, Gersh BJ. Prognostic value of treadmill exercise testing: a population-based study in Olmsted County, Minnesota. ***Circulation*** *2005; 98: 2836-2841.*

12. Arbag H Kentiz, Pellikka PA. Atropine for inconclusive exercise tests: A beautiful solution or just cosmetics? Am Heart, 2005; 145: 938-940.